The 20C2 agent represents a novel therapeutic tool for diminishing interleukin-12 's signaling . IL-12 functions a significant role in promoting pathological responses , particularly in chronic immunological states . By selectively interacting with the interleukin-12 subunit , this monoclonal antibody efficiently blocks interleukin-12 - induced signaling , leading to decreased immune activity and possible outcomes for suffering individuals .
Understanding the Role of 20C2 Anti-IL-12 Antibody in Immunological Research
The molecule is proving to be a important resource in biological analysis. Its specificity for IL-12, a significant cytokine participating in T helper 1 systemic reactions , facilitates experts to precisely explore the effect of IL-12 blockade on various pathological processes . This power has yielded significant insights into the origin of infectious disorders and suggests novel clinical options for prospective management .
20C2 Antibody: Specificity and Applications for IL-12 subunit p70 Suppression
The antibody 20C2 immunoglobulin exhibits high specificity for the IL-12 subunit p70 heterodimer , reliably suppressing its biological activity . Consequently , this specific antibody finds widespread utility in studies focused on inflammatory conditions , particularly where IL-12 driven processes plays a central part . Moreover, it serves as a useful reagent for assessing IL-12 pathways in cell culture and experimental models.
Mouse-Derived 20C2 Antibody: A Reliable Tool for IL-12 Pathway Studies
The mouse immunoglobulin provides a dependable tool for investigating the complex IL-12 pathway . Generated in response to engineered individual IL-12, this targeted agent exhibits robust binding and precision for the p40 of IL-12, enabling for accurate quantification and modulation of IL-12 effect. Researchers leverage this probe in a range of applications , such as :
- Flow staining to assess IL-12 release .
- ELISA assays for quantifying IL-12 levels .
- Neutralizing investigations to investigate IL-12's role in biological responses .
Its well-established performance makes it a critical component for progressing our knowledge of IL-12 physiology and its consequences in disease .
Exploring the Regulatory Action of 20C2 Anti- IL-12 Monoclonal Agent
The potential application of 20C2, a monoclonal immune directly targeting IL-12 p70, extends beyond merely reducing inflammatory responses. Recent evidence indicates important regulatory influence – including the modulation of T immune response and the shaping of acquired immune reactions. Further research is required to thoroughly elucidate the mechanisms underlying these intricate connections and to optimize its clinical utility in a variety of illness situations.
20C2Antibody: CharacterizationDescriptionAssessment and UtilityApplicationFunction in BlockingSuppressingInhibiting IL-12Interleukin-12IL-12 P40 ActivityFunctionalityResponse
The 20C220C2mAbmAb 20C2 antibodyimmunoglobulinIgG is a monoclonalmAbsspecific antibodyimmunoglobulinIg recognized for its abilitycapacitypotential to blockinterfere withneutralize IL-12IL-12p40interleukin 12 activityfunctionbiological effect. CharacterizationDetailed analysisThorough assessment demonstratesrevealsindicates that 20C220C2mAbmAb 20C2 specificallyselectivelyprimarily targets the p40IL-12p40subunit of IL-12IL-12p40interleukin 12, effectivelyefficientlysubstantially inhibitingreducingsuppressing its bindinginteractionengagement with IL-12IL-12p40interleukin 12 receptorsreceptorstargets on immunelymphoideffector cellspopulationslymphocytes. This propertycharacteristicfeature makes 20C2 anti‑IL‑12 p70 monoclonal antibody 20C220C2mAbmAb 20C2 a valuableusefulimportant toolreagentagent for investigatingstudyingexploring the rolefunctionimpact of IL-12IL-12p40interleukin 12 in variousdifferentseveral immunologicalinflammatorydisease processespathwaysconditions and providesofferspresents a therapeuticpotentialpromising strategyapproachmethod for blockingattenuatingreducing IL-12IL-12p40interleukin 12-mediated inflammationimmune responsedisease progression.